Conference

 

The start to finish of biologics

 

The Festival of Biologics brings together senior biologics professionals across the value chain to advance the industry to improve patient health. We cover the start to finish of biologics: from discovery to development, to manufacturing and market access.

 

The Americas Antibody Congress is America's best space for discussing topics such as protein engineering, bispecifics and mAbs.

AGENDA COMING SOON

 

At The World Immunotherapy Congress we cover themes such as Cell & Gene Therapy, Immune Check inhibitors and AI in oncology.

AGENDA COMING SOON

 

Biosimilars is bringing together leaders to share on sustainability, innovation and biobetters and patient engagement.

AGENDA COMING SOON

 

Previous Speakers

 

Antibody Speakers

 

Immunotherapy Speakers

 

Biosimilars Speakers

Timothy de Gavre
Chief Commercial Officer
Sandoz US
Hillel Cohen speaking at Festival of Biologics USA
Dr Juan Tapia Mendoza
Board Certified Pediatrician
SOMOS Community Care
Sameer Awsare speaking at Festival of Biologics USA
Gillian Woollett
VP, Head Regulatory Strategy and Policy
Samsung Bioepis US
Gillian Woollett speaking at Festival of Biologics USA
Emanuela Lacana
Deputy Director, Office of Therapeutic Biologics and Biosimilars/OND/CDER
FDA
Emanuela Lacana speaking at Festival of Biologics USA
 

 

Stay Up to Date

Join our mailing list to receive exclusive content and offers.

CONFERENCE TOPICS

AI and Machine Learning in Oncology and Biomarkers
Antibodies in Immunotherapy
Armed Antibodies
Biosimilar Development, Manufacturing and Analysis
Biosimilars in Healthcare Policy
Checkpoint Inhibitors
Clinical Trials
CMC, Developability and Manufacturability
Commercialization and Market Access
Commercialization of Biosimilars and Sustainability of the Industry
Neoantigens
New Technology in Screening and Analytics for Antibody Proteins
Non-Oncology Immunotherapy
Novel Indications for Therapeutic Antibodies
Oncolytic Viruses
The Clinical Environment and Real-world Evidence
Tumor Microenvironment
Value and affordability of Biosimilars